TX-MAVENIR
16.4.2024 13:01:29 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that the Mavenir Digital Enablement (MDE) is now available on Amazon Web Services (AWS) Marketplace.
Mavenir’s Digital Enablement (MDE) Business Support System (BSS) stack with composable architecture allows Communication Service Providers (CSPs) to implement innovative strategies and new selling models quickly, cost-effectively and with minimal risk, with the ability to test models iteratively and speed time-to-market without increasing capital and resource costs. MDE’s comprehensive set of modules already run on AWS – for reduced application-to-infrastructure test times – and span customer management, product catalog, order management, CRM, billing, converged charging, API monetization and network slice charging. With low-code/no-code visual builders and templated solutions-in-a-box, MDE is now available as a one-stop destination and digital marketplace for CSPs looking to implement new or complex models simply and agilely.
MDE offers a low-risk route to introducing profitable new business models such as split or sponsored billing, new package product offerings incorporating third-party solutions, automation for inter-partner manual tasks such as catalog mapping, and notifications mapping for service delivery to improve operational efficiency and the customer experience.
Mavenir’s Digital BSS has achieved platinum certification from TM Forum, with open APIs ensuring seamless integration with existing or new third-party systems and eliminating the need for resource-intensive system integration effort.
Sandeep Singh, Senior Vice President and General Manager for Mavenir’s Digital Business Enablement commented: “Mavenir’s Digital BSS is a transformative solution for service providers looking to stay ahead of the competition and launch innovative offerings in a fast time-to-market. Our arrival on AWS Marketplace is a strategic acceleration of our mission to drive sustainable global network automation and monetization, empowering the world’s operators to roll out advanced digital experiences at scale.”
He added: “By facilitating end-to-end digitization of customer interactions and streamlining collaboration with third-party partners – all within a stable and agile architecture – MDE Digital BSS provides service providers with a complete innovation framework to create seamless, personalized network service experiences for customers, and realize the gains with flexible monetization capabilities.”
John Abraham, Principal Analyst, Appledore Research noted: “One of the main innovation barriers for CSPs is the inflexibility of incumbent legacy BSS ecosystems, which require substantial investment in time, cost, and operational resources to enable new revenue models and service capabilities. Simplifying the path to the timely introduction of new business models and innovative best practices, as Mavenir is enabling with its MDE solution, provides CSPs with a distinct advantage in time to market and TCO.”
The MDE platform not only enables greenfield service providers to bring new services to market rapidly but also empowers brownfield service providers to modernize their legacy stack, accelerate digital transformation, and provides a viable path to migrate to 5G while co-existing with existing technologies (2G/3G/4G). MDE brings marketplace capabilities to service providers to cross sell 3rd Party Partner-led product and services integrated with CSPs and Mobile Virtual Network Operators (MVNOs) worldwide. The platform uses advanced AI-ML engines to derive intelligence from customer and network data, which is then used to recommend new products based on historical behavior, and also delivers categorization capabilities that enable service providers to fully capitalize on their rich datasets – bringing new revenues and boosting customer stickiness.
Notes to editors:
- More information about Mavenir’s Digital BSS:
https://www.mavenir.com/portfolio/mavapps/mavenir-digital-enablement-bss/
- Mavenir’s listing on AWS Marketplace:
https://aws.amazon.com/marketplace/pp/prodview-ylbqlsfj3bmay
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416395684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom